tTF-NGR - Tumour-targeted fusion protein for vascular blockade in cancer therapy
tTF-NGR is a fusion protein for targeted tumour therapy via vascular occlusion. Find out everything about the mechanism of action, application in cancer and current studies such as TRABTRAP.
Things worth knowing about "tTF-NGR (truncated Tissue Factor)"
tTF-NGR is a fusion protein for targeted tumour therapy via vascular occlusion. Find out everything about the mechanism of action, application in cancer and current studies such as TRABTRAP.
tTF-NGR is a biotechnologically produced fusion protein that specifically targets tumour-associated vessels. It combines two functional units:
- tTF (truncated tissue factor): a truncated form of human tissue factor that can activate blood clotting
- NGR peptide (Asn-Gly-Arg): a tumour-homing sequence that binds specifically to CD13-positive endothelial cells
selectively induce microthrombosis in tumour vessels, thereby interrupting the tumour's blood supply and cutting off the cancer cells from nutrient replenishment.
targeted antiangiogenic therapy for difficult-to-treat tumours, in particular:
- Soft tissue sarcomas (e.g. in the TRABTRAP study in combination with trabectedin)
- Colorectal carcinoma
- Hepatocellular carcinoma
tumour regression while maintaining systemic tolerability.
Advantages:
- Challenges:
- innovative drug approach that uses vascular occlusion therapeutically to selectively starve tumours. Thanks to its tumour selectivity, it offers the chance of effective yet tolerable therapies for aggressive cancers.
Literature references:
- Cancer Cell.
- Journal of Clinical Oncology.
- Nature Biotechnology.
- innovative drug approach that uses vascular occlusion therapeutically to selectively starve tumours. Thanks to its tumour selectivity, it offers the chance of effective yet tolerable therapies for aggressive cancers.
Literature references:
- Cancer Cell.
- Journal of Clinical Oncology.
- Nature Biotechnology.